Trial Profile
A multicentre, double-blind, randomised, parallel group, placebo-controlled trial of LAX-101 (ethyl eicosapentaenoate) as adjunct therapy in patients who remain depressed following treatment with standard antidepressant therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Oct 2016
Price :
$35
*
At a glance
- Drugs Ethyl eicosapentaenoic acid (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Sponsors Amarin Neuroscience
- 20 Oct 2006 New trial record.